Pharma IQ is announcing its 2011 clinical event series providing platforms for biotech and pharma professionals to initiate relationships and discuss challenges. The series includes 11 events focused on topics like oncology clinical development, clinical outsourcing, data standardization, clinical supply, and bioequivalence. The events will bring together senior industry experts through presentations and discussions to address issues like clinical trial design, data management, and regulatory requirements. Pharma IQ has over 40 years of experience organizing conferences and aims to provide a global platform to share knowledge and solutions.

1. Pharma IQ’s 2011
Clinical Event Series
Information Pack
IQPC is pleased to announce the launch of the 2011 clinical
event series providing high-level platforms to initiate and
cement new business relationships across the clinical space.
Specifically tailored events featuring senior experts from
across the biotech and pharma industry include:
• Optimising Clinical Development in Oncology
• Global Clinical Outsourcing Forum
• Clinical Data Standardisation and Management
• Phase I Clinical Development
• Clinical Trial Supply
• Optimising Clinical Development in CNS
• Successful Comparator Sourcing and Development
• Clinical Investigations and Evaluations for Medical Devices
• Bioavailability and Bioequivalence
• Innovation in Clinical Design, Analysis and Reporting
A golden opportunity to share knowledge,
concerns, solutions and promising developments
Bristol Myers Squibb

2. Featured speakers on our clinical event panels include:
• Tomas Skacel, International Medical Director, Amgen • Benedikte Akra, Medical Science Manager – Oncology, Bristol
• Ridwaan Jhetam, Global Clinical Operations Head: Oncology Myers Squibb
Senior Director, Johnson and Johnson • Christiane Langer, Group Medical Director, Oncology Clinical
• Mike Burgess, European Head of Oncology Clinical Research and Research Europe, Bristol Myers Squibb
Early Development, Roche • Susanne Kihlblom, Strategic Sourcing Leader, AstraZeneca R&D
• Grégory Coraux, Sourcing and Vendor Management, Merck • Richard Pompe, Global Procurement Director, Mylan
Serono • Anish Desai, Head R&D, Medical Director, Bayer Schering
• Michael Herschel, Director Clinical Research, GlaxoSmithKline Pharma India
• Michael Zaiac, Assistant Vice President, Medical Affairs EMEA, • Monika Kouba, Clinical Research Director CEE and Subregional
Transplant, Oncology and GI, Wyeth Head Clinical Operations Central Eastern Europe and Middle East,
• Thore Nederman, Head of Clinical Development, Active Biotech Schering-Plough
• Antonio Llamas, Regional Head of Operations Spain & Portugal, • Pasi Piitulainen, Global Clinical Development Affairs Director,
Wyeth Research Actelion
• Anne Maria Ylisaari, Head of In-and-Outsourcing, Orion Pharma • Pia Sauer, Outsourcing and Contract Manager, Clinical
• Estrella Garcia, Head of Global Clinical Operations and Strategic Development, Genmab
Resourcing, Almirall • Uwe Schneider, Global Head of Sourcing Management and Head
• Giorgio Massimini, Administrative Head of Oncology , Europe, of Development Office, Grünenthal
Roche • Nursah Omeroglu, Clinical Research Manager, Sanofi-Aventis
• Jai Balkissoon, Senior Medical Director, Director of Oncology, • Christian Hucke, Clinical Development Manager, Affimed
Oxigene • Esther Garcia Gil, Global Clinical Leader R&D, Respiratory
• Shanna Stopatschinskaja, Global Medical Director Oncology, Therapeutic Area, Almirall
Schering Plough • Sheila Weir, Head, Project Management, Newron Pharmaceuticals
2011 Clinical Series Events
Clinical Trial Supply Europe
26-27th January 2011, Rotterdam
www.clinicalsupplyeurope.com
With the latest statistics showing that an estimated 70% of clinical trials fail to complete on
time, clinical supply departments are under increased pressure to streamline processes and
cut time wherever possible. In response to industry demand, Pharma IQ’s Clinical Trial
Supply Europe conference will bring together senior industry experts from across the globe
to discuss innovative approaches to planning, packaging, distribution, comparator sourcing
and much more in three days of interactive presentations and discussions. Excellent.
2nd annual Optimising Clinical Development in Oncology
Very interesting
(Co-located with Clinical Development in CNS)
22-23 March 2011, Berlin/London
networking
www.oncologysummit.co.uk
With the oncology market now valued at $55 billion, pharma and biotech manufacturers are MSF Supply
under pressure to find innovative ways of speeding development times in order to claim
their share of this lucrative area. However, oncology poses unique patient recruitment, trial
design and operational challenges – issues that can waste invaluable resource and slow
regulatory approval. Through a series of interactive presentations and discussions, Pharma
IQ’s Optimising Clinical Development in Oncology conference provides a unique platform for
manufacturers to discuss practical, proven ideas to save time and money and ensure that
companies have the knowledge they need to take their drugs to market fast.
Optimising Clinical Development in CNS
(Co-located with Clinical Development in Oncology)
22-23 March 2011, Berlin/London
As the second largest therapeutic segment but with the fastest growth rate, the global CNS
market is forecast to expand to US$63.9 billion in 2010. Much like oncology however, several
challenges remain when it comes to conducting clinical trials within this therapy area
compounded by the recent FDA suicidality regulation that has left pharma companies
needing further clarification. Optimising Clinical Development in CNS provides a good
opportunity to discuss all the key challenges in an interactive event forum.

3. Successful Comparator Sourcing and Development
April 2011, Venue TBC
In response to an ever increasing number of global comparator clinical trials, it is
important for any company to ensure that comparator drugs are available for all trials.
However, with this task being fraught with challenges such as thee inability to obtain the
right documentation, lack of supply chain security and an increasing number of
counterfeits, as well as the high quality level of product needed, the opportunities for
success becoming harder to find. Pharma IQ's Successful Comparator Sourcing and Overall very
Development Conference will bring together senior thought leaders to address the knowledgeable. Very
numerous challenges faced by comparator professionals, offering a platform for in-depth
discussion to enable the birth of innovative answers to these key challenges valuable, good high level
summary of real life
2nd annual Global Clinical Outsourcing Forum
May 2011, Munich process excellence”
www.globalclinicaloutsourcing.com
Over the past few years outsourcing has become vastly popular among biotech and pharma Schering Plough
companies with an estimated third of all R&D budgets now being spent on CROs. As
rewarding as this practice can be, there are still multiple challenges to be faced when it
comes to outsourcing, particularly when it comes to choosing an outsourcing strategy, “The conference was
selecting a CRO, project managing the trial and ensuring that the company achieves the “perfect” in my
desired outcome in the desired timeline. This conference is focused on effectively
managing strategic and tactical outsourcing partners to maximise the efficiency of global personal opinion. From
trials and speed time to market for new drugs. Case studies from industry key players as last year I have received
well as interactive sessions will offer attendees a unique opportunity to interact and
exchange ideas with fellow experts facing similar challenges, assess the industry trends, 2 orders that started
maximise alliance opportunities and take advantage of the practical experience shared by during the meeting. I
the most knowledgeable experts in the business. hope we can at least
2nd annual Clinical Data Standardisation and Management repeat this number
June 2011, London based on this
www.clinicaldataevent.com
In a climate where streamlining processes and maximising resources is paramount,
conference. I don’t have
ensuring an efficient and effective approach to data management is integral to running a a total overview yet, but
trial on time and on budget. However, key challenges remain. With changes to CDISC I think we have picked
standards and the CDASH initiatives in place, implementing these initiatives at a company
level can be approached in a number of ways – some which are more successful than up about 10 leads and
others. Covering key areas such as effective approaches to standardisation, outsourcing the at least 30 great
data management function, best practice approaches to data warehouses, enhancing
efficiency and reducing costs and effective data migration methods, Pharma IQ’s Clinical contact”
Data Standardisation and Management event will provide a wealth of pharma and biotech
manufacturer case studies to ensure delegates take away practical techniques that they Avantium Technologies
can apply to their business.
2nd annual Innovation in Phase 1 Clinical Development
September 2011, Munich
www.phase1clinicaldevelopment.com
With the emphasis on speeding the go/no-go decision and saving clinical development costs
later down the line, annual spend on Phase 1 trials is up by 12.5% and a total of 40% of all
development projects are now in this stage. Increased spend has led to increased
innovation and companies are approaching trial design and exploratory development in
new ways in order to speed the process along. Pharma IQ’s Phase 1 Clinical Development
event will bring together key regulators and manufacturers to address core issues such as
regulatory requirements, changes to the ICH guidelines, microdosing studies and patient
recruitment amongst others, in order to aid manufacturers in their quest to reduce cost
and achieve a go/no-go decision faster.
2nd annual Clinical Investigations and Evaluations for Medical Devices
October 2011, Berlin, Germany
www.clinicalmedicaldevice.com
With the recent amendments to the Medical Device Directive (2007/47/EC), it is essential that
the medical device industry adapts their evaluations and investigations strategy to
maintain complete compliance. Pharma IQ’s Clinical Evaluations and Investigations for
Medical Devices Conference will bring together regulators, notified bodies, medical device
professionals and CRO’s all tasked with the same remit; medical device evaluations and
trials. This conference will offer attendees the opportunity to discuss the key challenges
currently being faced as well as possible solutions and also gain immediate clarification
over how best to implement the guidelines from the regulatory bodies represented.

4. 2nd annual Bioequivalence and Bioavailability
October 2011, Munich, Germany
www.bioequivalenceevent.com
Bioequivalence and bioavailability are an essential part of regulatory approval process for
generic and innovator companies and with the arrival of new EMA guidelines (on 1st August
2010) and the expanding scope of the generics market, it is now a crucial time to explore
the impact of these guidelines and the changes they are bringing. The guidelines permit
Overall very
increased flexibility regarding study design, as well as providing recommendations on BCS- knowledgeable. Very
based biowaivers and new approaches to study requirements for different dosage forms. valuable, good high level
The conference is bringing together several of the drafting committee to address these
changes to help optimise your bioequivalence studies. summary of real life
process excellence”
Innovation in Clinical Design, Analysis and Reporting
November 2011, London
www.clinicalreporting.co.uk Schering Plough
The world of clinical trials is evolving. More trials are taking place than ever before and
the last 18 months have seen a flood of regulation in the biostatistics arena, with the “The conference was
EMA laying down new rules on missing data and the FDA publishing new guidelines on
adaptive trials. Getting your design, analysis and reporting right to cut time and costs “perfect” in my
has never been more important.Pharma IQ’s Innovation in Clinical Design, Analysis and personal opinion. From
Reporting conference will help to open up this area to debate, facilitate discussion
between like-minded professionals within the field, presenting industry professionals last year I have received
with a forum for learning new developments and the networking potential to forge 2 orders that started
lasting business relationships. during the meeting. I
hope we can at least
repeat this number
based on this
conference. I don’t have
a total overview yet, but
I think we have picked
up about 10 leads and
at least 30 great
About Pharma IQ contact”
Pharma IQ has been rated again and again as the most effective business Avantium Technologies
development event partner!
Pharma IQ is a division of IQPC. Founded in 1973, IQPC now has offices in major cities
across six continents, giving Pharma IQ a truly global reach. The international
research base ensures Pharma IQ is uniquely positioned to put together our leading
events, tackling the issues important to you and bringing tangible benefits to your
organisation. As an organisation, we have educated and trained over two million
executives at over 40,000 conferences and training courses worldwide.
The European arm, based in our London office, has grown an enviable reputation
for quality and now widely recognised as a market leader in specialist
pharmaceutical conferences.
Pharma IQ works closely with a number of industry organisations to deliver
cutting edge conferences that showcase the latest requirements, emerging
technologies and practical solutions in the area. The international speakers and
audiences at each event ensure that the need for communication between the
pharmaceutical community. With ample opportunity for networking, these events
represent an unparalleled platform to gather information, meet key customers and
develop business.